GlaxoSmithKline
NEWS
Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
Jack Bailey, head of the company’s U.S. pharmaceuticals business is stepping down at the end of the year.
The vaccines are for Ebola Zaire, Ebola Sudan and the Marburg virus. Currently no licensed vaccines against these three viruses are available. All three diseases have a death rate of about 50%.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
It’s no secret that artificial intelligence and machine learning play key roles in drug development. This week, multiple companies have advanced their AI programming.
According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
The two-drug combination of Dovato provided similar long-term viral suppression to common three-drug regimens.
MorphoSys AG announced that its licensing partner GSK reported in a press release earlier the start of a phase 3 clinical development program with otilimab in rheumatoid arthritis.
JOBS
IN THE PRESS